We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01564498
Recruitment Status : Recruiting
First Posted : March 27, 2012
Last Update Posted : October 26, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
The hypothesis is that richly coloured purple vegetables, rich in polyphenolic compounds including anthocyanins will have higher antioxidant and other biological activities, than more lightly coloured versions of these foods. Diets of human subjects will be modified to allow consumption of 200-300 g of raw carrots or cooked potatoes. Participants will be randomized to consume either orange or purple carrots, or white or purple potatoes. They will consume these diets for 12 weeks and bioavailability of polyphenolics will be examined as well as anthropometry and blood biochemistry for changes in risk factors associated with cardiovascular disease.

Condition or disease Intervention/treatment Phase
Hypertension Hypercholesterolemia Type II Diabetes Obesity Inflammation Other: vegetable Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Pilot Study of the Effects of Replacing Orange Carrots and White Potatoes With Purple Varieties, on Risk Factors for Cardiovascular Disease
Study Start Date : April 2012
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017
Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: White potato
Participants will consume 300-500 g of cooked white potatoes per day
Other: vegetable
200-300 g raw carrots or 300-500 g cooked potatoes
Experimental: Purple Potato
Participants will consume 300-500 g of cooked purple potato per day
Other: vegetable
200-300 g raw carrots or 300-500 g cooked potatoes
Placebo Comparator: Orange carrots
Participants will consume 200-300 g typical varieties of orange carrots during the intervention
Other: vegetable
200-300 g raw carrots or 300-500 g cooked potatoes
Experimental: Purple Carrots
Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
Other: vegetable
200-300 g raw carrots or 300-500 g cooked potatoes

Outcome Measures

Primary Outcome Measures :
  1. Blood cholesterol [ Time Frame: 12 weeks ]
    blood will be collected at baseline before the experimental foods are introduced and again 6 weeks into the intervention period and during the last week of the intervention (week 12)

Secondary Outcome Measures :
  1. blood pressure [ Time Frame: 12 weeks ]
    Participants will have their body weight and blood pressure taken at weekly counselling sessions

  2. body composition [ Time Frame: 12 weeks ]
    body composition will be measured in well hydrated subjects using bioelectric impedence analysis

  3. insulin resistance [ Time Frame: 12 weeks ]
    insulin resistance will be measured by way of an oral glucose tolerance test and collection of venous blood samples for the subsequent 3 hours on two occasions, baseline and during the last week of the intervention diet.

  4. blood and urinary polyphenol metabolites [ Time Frame: 12 weeks ]

    venous blood and urine will be collected to determine the metabolic profiles of polyphenolics in individual participants.

    Based on intake data, the bioavailability of the polyphenols in the foods will be estimated.

  5. circulating biomarkers of cardiovascular disease and type II diabetes risk [ Time Frame: 12 weeks ]
    Blood will be collected for measurement of multiple cytokines, growth factors and other blood biomarkers associated with these diseases.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult men and women 18-65 years of age
  • must have a least one of the following risk factors associated with increased risk of type II diabetes and/or cardiovascular disease:

    • borderline high or hypertension or undergoing treatment for such
    • abnormal fasting blood glucose or undergoing treatment for such
    • overweight or obese
    • borderline high or high LDL-cholesterol or undergoing treatment for such
    • borderline low or low HDL-cholesterol
    • borderline high or high triglycerides or undergoing treatment for such

Exclusion Criteria:

  • smokers, pregnant or nursing women
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01564498

Contact: Kelly A Meckling, PhD 5198244120 ext 53742 kmecklin@uoguelph.ca
Contact: Saqib Mannan, BSc 5198244120 ext 53728 smannan@uoguelph.ca

Canada, Ontario
Human Nutraceutical Research Unit Recruiting
Guelph, Ontario, Canada, N1G2W1
Contact: Amanda J Wright, PhD    5198244120 ext 54697    ajwright@uoguelph.ca   
Contact: Amy Tucker, PhD    5198244120 ext 53925      
Principal Investigator: Kelly A Meckling, PhD         
Sub-Investigator: Saqib Mannan, BSc         
Sub-Investigator: Ricky Janssen, BSc         
Sponsors and Collaborators
University of Guelph
Ontario Ministry of Agriculture, Food and Rural Affairs
More Information

Responsible Party: Kelly Anne Meckling, PhD, Professor, University of Guelph
ClinicalTrials.gov Identifier: NCT01564498     History of Changes
Other Study ID Numbers: 2012MeckPurpleVeg
First Posted: March 27, 2012    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Kelly Anne Meckling, PhD, University of Guelph:
insulin sensitivity
glucose tolerance
metabolic syndrome

Additional relevant MeSH terms:
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Pathologic Processes
Lipid Metabolism Disorders
Metabolic Diseases
Diabetes Mellitus
Glucose Metabolism Disorders
Endocrine System Diseases